OUR MISSION

At Inflammatix, we are reimagining diagnostics

Inflammatix will create and commercialize best-in-class host-response diagnostics to resolve major clinical and public health challenges.

Better patient care is at the core of what we do. We achieve better patient care through our innovative approach to developing diagnostics–our tests read the patient’s immune system to help us understand the cause of infection and the degree of its severity. Armed with this knowledge, the clinician can treat the patient appropriately and within minutes.

Precision medicine on demand

There is a critical unmet need for quickly and accurately characterizing infections in patients who are acutely ill. Our expert bioinformatics and assay development teams are building a host response-based diagnostics pipeline that includes tests for acute infection and sepsis, emerging infectious diseases, autoimmune diseases, tropical infections, transplant rejection and other conditions.

We are initially focused on developing tests for acute bacterial infections, viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.

Inflammatix-diagnostics

Leadership

Tim Sweeney, MD, PhD
Tim Sweeney, MD, PhDCo-Founder and CEO
Bio
Jonathan Romanowsky
Jonathan RomanowskyCo-Founder and Chief Business Officer
Bio
Purvesh Khatri, PhD
Purvesh Khatri, PhDCo-Founder and Chief Scientist
Bio
Oliver Liesenfeld, MD
Oliver Liesenfeld, MDChief Medical Officer
Bio
Joao Fonseca, PhD
Joao Fonseca, PhDChief Technology Officer
Bio
Ljubomir Buturovic, PhD
Ljubomir Buturovic, PhDVice President of Machine Learning
Bio
Paul Fleming, PhD
Paul Fleming, PhDVice President of Engineering
Bio
Diana Lane
Diana LaneVice President of Quality Assurance and Regulatory Affairs
Bio
Tawny Darling
Tawny DarlingVice President of People Operations
Bio
Jerry Ceglia
Jerry CegliaVice President of Operations
Bio
Christopher MacGriff, PhD
Christopher MacGriff, PhDVice President of Strategy and Corporate Development
Bio
Ashley Prasse Miller
Ashley Prasse MillerVice President of Clinical Operations
Bio
Jennee DeVore
Jennee DeVoreVice President of Legal
Bio

Board of Directors

Tim Sweeney, MD, PhD
Tim Sweeney, MD, PhDCo-Founder and CEO
Bio
Jonathan Romanowsky
Jonathan RomanowskyCo-Founder and Chief Business Officer
Bio
Steve Tablak
Steve TablakFormer Chairman and CEO, GeneWeave
Bio
Ingo Chakravarty
Ingo ChakravartyOperating Partner, Northpond Ventures
Bio
Heiner Dreismann, PhD
Heiner Dreismann, PhDFormer CEO, Roche Molecular Systems
Bio
David Persing, MD, PhD
David Persing, MD, PhDEVP/Chief Medical Officer, Cepheid
Bio

Advisors

Ken Bahk, PhD
Ken Bahk, PhDCEO of Lakewood Holdings
Bio
Nathan A Ledeboer
Nathan A LedeboerProfessor and Vice Chair of Pathology
Bio
Jim Ducharme
Jim DucharmeClinical Professor of Medicine
Bio
Laura L. Adams
Laura L. AdamsSpecial Advisor at the National Academy of Medicine (NAM)
Bio
Mario Torres
Mario Torres Diagnostic device and molecular diagnostics testing
Bio

In Memoriam

In memory of our valued scientific advisory board member and close friend.

Hector Wong, MD
Hector Wong, MDProfessor of Pediatrics
Bio

Investors

Inflammatix investors include the following groups:

d1-capital-investor logo
greysky-equallogo

Partner with Us!

Inflammatix is establishing partnerships with diagnostic instrument, companion therapeutic and commercial distribution companies across the globe. Contact us at [email protected] to explore collaboration opportunities.

Our current and past partners include Genentech, NIH, DRIVe, BARDA and DARPA

Awards

Inflammatix is recognized for our accomplishments and promise

2021 SCCM Gold Snapshot Award for the 50th Critical Care Congress

Tracxn Emerging Startups 2021: Top Diagnostics Tech Startups

medtech-400

2020 MedTech Innovator Top 50 Medtech Startups

2019 FierceMedTech Fierce 15 Company

2019 AACC Disruptive Technology and Audience Choice Awards

2017 ISF Best Clinical Abstract Award

Stay in touch with social updates:
Find out the latest news.